Which metabolites target DNA polymerase and ribonucleotide reductase?

Which metabolites target DNA polymerase and ribonucleotide reductase?

• A. Cytarabine, Gemcitabine, Fludarabine, Cladribine
• B. Methotrexate, 5-Fluorouracil, Capecitabine, Cladribine
• C. Dihydrofolate, TMP, dUMP, THF
• D. Methotrexate, Cytarabine, Cladribine, Thymidylate

Answer: (A)

The correct answer identifies a group of nucleoside analogs that specifically target DNA polymerase and ribonucleotide reductase, important enzymes in DNA synthesis and repair mechanisms. Cytarabine, Gemcitabine, Fludarabine, and Cladribine are all known for their roles as antimetabolites that interfere with nucleic acid synthesis. They mimic natural nucleotides and can be incorporated into DNA or RNA, leading to chain termination or inhibition of replication. Cytarabine and Gemcitabine primarily inhibit DNA polymerase during DNA replication, thus affecting rapidly dividing cells often seen in cancers. Fludarabine and Cladribine also disrupt nucleotide metabolism by targeting ribonucleotide reductase, an enzyme critical for converting ribonucleotides to deoxyribonucleotides, which are necessary for DNA synthesis and repair. Together, these drugs create a multifaceted approach to inhibit cancer cell proliferation by specifically interfering with the pathways that allow for DNA and RNA synthesis, making this option accurate in terms of the mechanisms involved. This targeting effectively contributes to their utility in treating various malignancies, particularly hematologic cancers. In contrast, the other options contain drugs or metabolites that either do not specifically target

The correct answer identifies a group of nucleoside analogs that specifically target DNA polymerase and ribonucleotide reductase, important enzymes in DNA synthesis and repair mechanisms.

Cytarabine, Gemcitabine, Fludarabine, and Cladribine are all known for their roles as antimetabolites that interfere with nucleic acid synthesis. They mimic natural nucleotides and can be incorporated into DNA or RNA, leading to chain termination or inhibition of replication.

Cytarabine and Gemcitabine primarily inhibit DNA polymerase during DNA replication, thus affecting rapidly dividing cells often seen in cancers. Fludarabine and Cladribine also disrupt nucleotide metabolism by targeting ribonucleotide reductase, an enzyme critical for converting ribonucleotides to deoxyribonucleotides, which are necessary for DNA synthesis and repair.

Together, these drugs create a multifaceted approach to inhibit cancer cell proliferation by specifically interfering with the pathways that allow for DNA and RNA synthesis, making this option accurate in terms of the mechanisms involved. This targeting effectively contributes to their utility in treating various malignancies, particularly hematologic cancers.

In contrast, the other options contain drugs or metabolites that either do not specifically target